
Laura L Hester

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4594415/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Update on prevalence of diagnosed systemic lupus erythematosus (SLE) by major health insurance types in the US in 2016. BMC Research Notes, 2022, 15, 5.	1.4	Ο
2	Diagnostic delay and characterization of the clinical prodrome in AL amyloidosis among 1523 US adults diagnosed between 2001 and 2019. European Journal of Haematology, 2021, 107, 428-435.	2.2	18
3	Characteristics and Outcomes of Over 300,000 Patients with COVID-19 and History of Cancer in the United States and Spain. Cancer Epidemiology Biomarkers and Prevention, 2021, 30, 1884-1894.	2.5	6
4	Risk of depression, suicide and psychosis with hydroxychloroquine treatment for rheumatoid arthritis: a multinational network cohort study. Rheumatology, 2021, 60, 3222-3234.	1.9	20
5	Risk of hydroxychloroquine alone and in combination with azithromycin in the treatment of rheumatoid arthritis: a multinational, retrospective study. Lancet Rheumatology, The, 2020, 2, e698-e711.	3.9	117
6	DIAGNOSTIC DELAY AND CHARACTERIZATION OF THE CLINICAL PRODROME IN AL AMYLOIDOSIS RELATED CARDIOMYOPATHY AMONG 1,173 PATIENTS DIAGNOSED BETWEEN 2001-2018. Journal of the American College of Cardiology, 2020, 75, 900.	2.8	1
7	Acute pancreatitis risk in type 2 diabetes patients treated with canagliflozin versus other antihyperglycemic agents: an observational claims database study. Current Medical Research and Opinion, 2020, 36, 1117-1124.	1.9	3
8	Diabetic ketoacidosis in patients with type 2 diabetes treated with sodium glucose coâ€transporter 2 inhibitors versus other antihyperglycemic agents: An observational study of four US administrative claims databases. Pharmacoepidemiology and Drug Safety, 2019, 28, 1620-1628.	1.9	36
9	Comparison of Medicare Claims-based Proxy Measures of Poor Function and Associations With Treatment Receipt and Mortality in Older Colon Cancer Patients. Medical Care, 2019, 57, 286-294.	2.4	13
10	Causeâ€specific mortality among Medicare beneficiaries with newly diagnosed nonâ€Hodgkin lymphoma subtypes. Cancer, 2019, 125, 1101-1112.	4.1	16
11	Diagnostic Delay and Characterization of the Clinical Prodrome in AL Amyloidosis: Data from 1,313 US Commercially Insured Patients between 2006-2018. Blood, 2019, 134, 5517-5517.	1.4	2
12	Publication of comparative effectiveness research has not increased in high-impact medical journals, 2004-2013. Journal of Clinical Epidemiology, 2017, 84, 185-187.	5.0	4
13	Reply to: comparative effectiveness medicines research cannot assess efficacy. Journal of Clinical Epidemiology, 2017, 92, 130-132.	5.0	0
14	Methodologic Issues when Estimating Risks in Pharmacoepidemiology. Current Epidemiology Reports, 2016, 3, 285-296.	2.4	31
15	Patterns of comorbidity among older U.S. patients with non-Hodgkin lymphoma Journal of Clinical Oncology, 2016, 34, 304-304.	1.6	3